GlassScriptPhysician profile
Carrie E Reif
NPI 1164668927
$1,768.58
in general payments reported to CMS, 2019-2025
23 companies · $655 in 2025
The $655 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $148 · 2022: $286 · 2023: $246 · 2024: $433 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,334.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $278.58 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $235.90 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $209.16 | 2024-2025 | Airsupra |
| Lilly USA, LLC | $151.05 | 2021-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $139.72 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $120.44 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $91.03 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Pfizer INC. | $88.72 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.47 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $59.42 | 2024-2025 | |
| Inspire Medical Systems, INC. | $43.03 | 2024 | Inspire |
| Biohaven Pharmaceuticals, INC. | $42.50 | 2021 | |
| Janssen Pharmaceuticals, INC | $36.13 | 2025 | Spravato |
| Glaxosmithkline, LLC. | $32.38 | 2023 | Shingrix |
| Idorsia Pharmaceuticals US INC | $24.55 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vbi Vaccine (Delaware) INC. | $24.27 | 2022 | |
| Corcept Therapeutics | $20.81 | 2022 | |
| Sanofi Pasteur INC. | $20.08 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.55 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.02 | 2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $13.81 | 2025 | Zoryve |
| Amgen INC. | $13.56 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Reif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.